By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A new company called Oxford Cancer Biomarkers has been formed to provide oncology consulting services and new cancer biomarkers.

The company, which is headquartered in Oxford and Reading, UK, is developing new biomarkers using CancerNav, a DNA- and protein-based assay technology platform developed by Nick La Thangue, chair of cancer biology at Oxford University, and David Kerr, professor of cancer medicine at the university.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.